Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Phathom Pharmaceuticals (PHAT) Long-Term Debt Issuances (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $173.2 million as the latest value for Q1 2026.

  • For Q1 2026, Long-Term Debt Issuances changed N/A year-over-year to $173.2 million; the TTM value through Mar 2026 reached $173.2 million, up 250.0%, while the annual FY2024 figure was $59.4 million, 51.08% up from the prior year.
  • Long-Term Debt Issuances hit $173.2 million in Q1 2026 for Phathom Pharmaceuticals, up from $24.8 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $173.2 million in Q1 2026 and bottomed at $9.9 million in Q1 2024.
  • Average Long-Term Debt Issuances over 3 years is $54.4 million, with a median of $24.8 million recorded in 2024.
  • On a YoY basis, Long-Term Debt Issuances climbed as much as 37.05% in 2024 and fell as far as 37.05% in 2024.
  • Phathom Pharmaceuticals' Long-Term Debt Issuances stood at $39.3 million in 2023, then plummeted by 37.05% to $24.8 million in 2024, then skyrocketed by 600.0% to $173.2 million in 2026.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $173.2 million, $24.8 million, and $24.8 million for Q1 2026, Q4 2024, and Q2 2024 respectively.